Literature DB >> 25600218

Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Jesús Rodríguez-Baño1, José Miguel Cisneros2, Nazaret Cobos-Trigueros3, Gema Fresco4, Carolina Navarro-San Francisco5, Carlota Gudiol6, Juan Pablo Horcajada7, Lorena López-Cerero8, José Antonio Martínez3, José Molina8, Milagro Montero7, José R Paño-Pardo5, Alvaro Pascual9, Carmen Peña6, Vicente Pintado4, Pilar Retamar8, María Tomás10, Marcio Borges-Sa11, José Garnacho-Montero12, Germán Bou10.   

Abstract

The spread of multidrug-resistant Enterobacteriaceae related to the production of extended-spectrum β-lactamases and carbapenemases is a serious public health problem worldwide. Microbiological diagnosis and therapy of these infections are challenging and controversial. Clinically relevant questions were selected and the literature was reviewed for each of them. The information from the selected articles was extracted and recommendations were provided and graded according to the strength of the recommendations and quality of the evidence. The document was opened to comments from the members from the Spanish Society of Infectious Diseases and Clinical Microbiology, which were considered for inclusion in the final version. Evidence-based recommendations are provided for the use of microbiological techniques for the detection of extended-spectrum β-lactamases and carbapenemases in Enterobacteriaceae, and for antibiotic therapy for invasive/severe infections caused by these organisms. The absence of randomised controlled trials is noteworthy; thus, recommendations are mainly based on observational studies (that have important methodological limitations), pharmacokinetic and pharmacodynamics models, and data from animal studies. Additionally, areas for future research were identified.
Copyright © 2014 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Carbapenemasas; Carbapenemases; Enterobacteriaceae multirresistentes; Extended-spectrum β-lactamase; Guidelines; Guía; Multidrug-resistant Enterobacteriaceae; Therapy; Tratamiento; β-lactamasas de espectro extendido

Mesh:

Year:  2015        PMID: 25600218     DOI: 10.1016/j.eimc.2014.11.009

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  9 in total

1.  Should we take into account ESBLs in empirical antibiotic treatment?

Authors:  Matteo Bassetti; Jesús Rodríguez-Baño
Journal:  Intensive Care Med       Date:  2016-10-21       Impact factor: 17.440

2.  Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacterales and Pseudomonas aeruginosa.

Authors:  J M López-Pintor; C Navarro-San Francisco; J Sánchez-López; A García-Caballero; E Loza Fernández de Bobadilla; M I Morosini; R Cantón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-02       Impact factor: 3.267

3.  Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.

Authors:  Isabel Machuca; Belén Gutiérrez-Gutiérrez; Irene Gracia-Ahufinger; Francisco Rivera Espinar; Ángela Cano; Julia Guzmán-Puche; Elena Pérez-Nadales; Clara Natera; Marina Rodríguez; Rafael León; Juan J Castón; Fernando Rodríguez-López; Jesús Rodríguez-Baño; Julián Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 4.  Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.

Authors:  Johann D D Pitout; Patrice Nordmann; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

5.  Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae: Epidemiological, Microbiological, and Clinical Features.

Authors:  José Ramón Paño-Pardo; Beatriz López Quintana; Fernando Lázaro Perona; Guillermo Ruiz Carrascoso; María Pilar Romero-Gómez; Belén Loeches Yagüe; Beatriz Díaz-Pollán; Ana Martínez-Virto; Jesús Mingorance; Julio García Rodríguez; José Ramón Arribas; Rosa Gómez-Gil
Journal:  Open Forum Infect Dis       Date:  2016-08-01       Impact factor: 3.835

6.  EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study.

Authors:  Belén Gutiérrez-Gutiérrez; Jesús Sojo-Dorado; José Bravo-Ferrer; Nienke Cuperus; Marlieke de Kraker; Tomislav Kostyanev; Lul Raka; George Daikos; Jan Feifel; Laura Folgori; Alvaro Pascual; Herman Goossens; Seamus O'Brien; Marc J M Bonten; Jesús Rodríguez-Baño
Journal:  BMJ Open       Date:  2017-04-03       Impact factor: 2.692

7.  Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial.

Authors:  Alicia Marín-Candón; Clara M Rosso-Fernández; Natalia Bustos de Godoy; Lorena López-Cerero; Belén Gutiérrez-Gutiérrez; Luis Eduardo López-Cortés; Lydia Barrera Pulido; Irene Borreguero Borreguero; María José León; Vicente Merino; Manuel Camean-Fernández; Pilar Retamar; Elena Salamanca; Alvaro Pascual; Jesús Rodriguez-Baño
Journal:  BMJ Open       Date:  2021-09-27       Impact factor: 2.692

8.  Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project.

Authors:  Zaira R Palacios-Baena; Lucia Valiente de Santis; Natalia Maldonado; Clara M Rosso-Fernández; Irene Borreguero; Carmen Herrero-Rodríguez; Salvador López-Cárdenas; Franciso J Martínez-Marcos; Andrés Martín-Aspas; Patricia Jiménez-Aguilar; Juan J Castón; Francisco Anguita-Santos; Guillermo Ojeda-Burgos; M Pilar Aznarte-Padial; Julia Praena-Segovia; Juan E Corzo-Delgado; M Ángeles Esteban-Moreno; Jesús Rodríguez-Baño; Pilar Retamar
Journal:  BMJ Open       Date:  2020-07-31       Impact factor: 2.692

9.  [Risk factors and clinical evolution of carbapenemase-producing Klebsiella pneumoniae infections in a university hospital in Spain. Case-control study].

Authors:  V Rojo; P Vázquez; S Reyes; L Puente Fuertes; M Cervero
Journal:  Rev Esp Quimioter       Date:  2018-09-18       Impact factor: 1.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.